Technology

Hybrid capture-based next generation sequencing

 

Personalized cancer therapies, based on the individual genetic tumor profile of the patient have led to a paradigm shift in oncology in recent years. An increasing number of genetic changes involved in tumor progression have been identified that can be successfully treated with targeted therapies.

In order to diagnose cancer reliably or understand it comprehensively within the framework of translational research, technologies for efficient molecular analysis of the tumour profile must be applied.

The NEO technology is suitable for analyzing solid tumors regardless of the indication and myeloid malignancies* in routine diagnostics and clinical research.

It reliably detects point mutations, small insertions and deletions, copy number alterations and translocations in oncogenes and tumor suppressors. In addition, microsatellite instability (MSI) and tumor mutational burden* (TMB) can be tested in tissue samples. The analysis can be performed on routine clinical tissue samples (FFPE, cryosections, cytologies) or blood.

NEO is based on “hybrid-capture next generation sequencing (NGS)” technology, and offers the possibility of an efficient and time-saving parallel multiplex analysis of tumor and therapy-relevant gene segments. This novel approach has made time-consuming single gene sequencing PCR-based detection methods or fluorescence in situ hybridization (FISH) analysis obsolete.

First, the genes of interest are extracted from the genome of the tumor using complementary probes (hybrid capture). The baits ensure optimal selection of therapy and tumor progression-relevant genes. Upon binding to the baits, all targeted fragments are amplified (clonal amplification) and sequenced in parallel. 

The NEO technology includes a complete bioinformatic analysis of the sequencing data obtained. Mutations, small insertions and deletions, amplifications and translocations can be reliably identified and examined for their therapeutic or diagnostic relevance. The derived data provide a rational basis for molecular cancer diagnostics or the reliable research on the cancer in clinical laboratories.

All molecular genetic tests developed by NEO New Oncology can be performed and evaluated directly in our customers' laboratories: Assays

NEO New Oncology offers comprehensive support in establishing the technology: NEOonsite

  

 


Kontakt

Telephone

Office: +49.221.888.23 80

Address

NEO New Oncology GmbH
Gottfried-Hagen-Str. 20
51105 Cologne
Germany

ImprintPrivacy policy

Newoncology.com uses cookies to make the website more user-friendly. By continuing to use the website, you agree to the use of cookies. If you do not agree to the storage of cookies, you will find further information HERE.

ok